Vaccinex Presents Updated Interim Results from a Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer at the 2019 ASCO Annual Meeting
Vaccinex, Inc. (VCNX)
Company Research
Source: GlobeNewswire
ROCHESTER, N.Y., June 03, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that updated interim results of the Phase 1b/2 study of pepinemab in combination with avelumab in non-small cell lung cancer (NSCLC) subjects were reported during a poster session on Saturday, June 1 at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Michael Shafique, M.D., Assistant Professor of Thoracic Oncology at the H. Lee Moffitt Cancer Center and Research Institute and first author of the presentation, presented “Interim results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC” during the Developmental Immunotherapy and Tumor Immunobiology poster session. Interim Results This ongoing Phase 1b/2, open label, single arm, first-in-human combination study is designed to eva
Show less
Read more
Impact Snapshot
Event Time:
VCNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCNX alerts
High impacting Vaccinex, Inc. news events
Weekly update
A roundup of the hottest topics
VCNX
News
- Vaccinex Reports 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Vaccinex Reports 2023 Financial Results and Provides Corporate UpdateGlobeNewswire
- Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
- Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswire
- Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology [Yahoo! Finance]Yahoo! Finance
VCNX
Sec Filings
- 4/26/24 - Form S-3
- 4/25/24 - Form 10-K/A
- 4/22/24 - Form 4
- VCNX's page on the SEC website